Please note that this meeting will take place as an in-person event in Boston, Massachusetts and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

Friday, July 24

• Networking Breakfast
• Novel Therapeutics: Biotech Spotlight Session 2
• Keynote Lecture
• Plenary Sessions 5-6
  • Plenary Session 5: Degraders in the Era of Precision Oncology
  • Plenary Session 6: From RAS Inhibitors to RAS Degraders
• Closing

Networking Breakfast

7-8 a.m. | Independence Ballroom West

Novel Therapeutics: Biotech Spotlight Session 2

8-9:30 am | Grand Ballroom

Moderators: Christiana Bardon, MPM BioImpact, Boston, Massachusetts, Michael A. Caligiuri, City of Hope National Medical Center, Duarte, California, and William N. Hait, Johnson & Johnson (ret.), New Brunswick, New Jersey

Break

9:30-9:45 a.m. | Grand Ballroom Prefunction

Keynote Lecture

9:45-10:45 a.m.

• 9:50 a.m. | Keynote Lecture
  William G. Kaelin, Dana-Farber Cancer Institute, Boston, Massachusetts
• 10:30 a.m. | Q&A

Break

10:45-11 a.m. | Grand Ballroom Prefunction

Plenary Sessions 5-6

11 a.m-1 p.m.

Plenary Session 5: Degraders in the Era of Precision Oncology

Grand Ballroom
Session Chair: Danette Daniels, Foghorn Therapeutics, Cambridge, Massachusetts

• 11:05 a.m. | Challenges and opportunities in PROTAC vs small molecule inhibitors
  Danette L. Daniels
• 11:25 a.m. | Chinatsu Sakata, Astellas, Ibaraki, Japan
• 11:45 a.m. | Induced proximity: Any target, every time
  Ryan Potts, Amgen, Thousand Oaks, California
• 12:05 p.m. | RIPTACs: A Novel, powerful modality to treat patients with prostate cancer and other diseases
  David Puleo, Halda Therapeutics, New Haven, Connecticut
• 12:25 p.m. | Panel Discussion

Plenary Session 6: From RAS Inhibitors to RAS Degraders

Constitution Ballroom A
Session Chair: Rona Yaeger, Memorial Sloan Kettering Cancer Center, New York, New York

• 9:20 a.m. | Development of KRAS G12D degraders
  Kathryn Smith, Arvinas, New Haven, Connecticut
• 9:40 a.m. | Andreas Mantoulidis, Boehringer Ingelheim, Vienna, Austria
• 10 a.m. | Novel molecular glue degraders to target KRAS mutants
  Anita C. Bellail, HB Therapeutics, Indianapolis, Indiana
• 10:20 a.m. | Ignacio Garrido-Laguna, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah
• 10:50 a.m. | Panel Discussion

Closing Comments and Departure

1 p.m.